Drug intelligence / Profile preview

ABBV-901

Development stage: Unknown
Lead developer: AbbVie
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABBV-901 is an investigational antibody-drug conjugate (ADC) being developed by AbbVie for the treatment of folate receptor (FR)-positive solid tumors, specifically targeting ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The drug is designed to selectively bind to the folate receptor on the surface of cancer cells, allowing for the targeted delivery of a cytotoxic payload directly into the tumor cells while minimizing exposure to healthy tissues. ABBV-901 is currently in Phase 1 clinical development, where it is being evaluated as a monotherapy and in combination with bevacizumab, particularly for patients with platinum-resistant ovarian cancer.

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on ABBV-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-901.

Explore the full profile